2nd Annual Biosimilars Summit

February 2016



Kempinski Hotel Bristol

Kurfürstendamm 27, 10719

About Summit

This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, regulatory advises and strategies for Biosimilars development. As biosimilars are now being developed and manufactured using todays state of the art technology and techniques, they can potentially also offer some benefits, in addition to cost, over the reference biologics. It is proved that Biosimilars could save the U.S. health system close to $44 billion in the next ten years. #BiosimilarsBerlin

Who Should Attend

Chief Executives, Executive Directors, VPs, Department Heads, Team Leaders and Managers from:

  • Biologics/Biotechnology/ Biogenerics
  • Legal Affairs
  • Pricing and Reimbursement
  • Regulatory Compliance
  • Preclinical and Clinical Development
  • Quality Affairs/ Quality Control
  • Biopharmaceuticals
  • Intellectual property
  • Clinical Immunology
  • R&D
  • New Product Development
  • Pharmacovigilance

From Industries Including:

  • Clinical Immunology
  • Immunology
  • Drug Safety
  • Preclinical Development
  • Therapeutic Areas
  • Business Development
  • Vaccines Development
  • Scientific Affairs
  • Global Strategy
  • Antibody Engineering
  • Oncology
  • Infection and Immunity
  • Risk Management
  • Clinical Program
  • Personalized Medicine
  • Portfolio Planning
  • Regulatory Affairs
  • Validation
  • Analytical Characterization
  • Antibody Discovery
Key Practical Learning Points of the Summit

The latest trends of the biosimilars
Successful commercialization of biosimilars in Europe and USA
Biosimilars in emerging markets – Regulatory and commercial considerations
Industry partnerships: Key success factor to win in biosimilar space
Regulatory advice on designing biosimilar trials
Totality of evidence and what it means to clinician
Experience of global clinical biosimilar trials
Strategies and competing products for a successful commercialization
Catherine Godrecka-Bareau

Director Portfolio Management & Strategy – Biosimilars


Dr. Edward Abrahams


Personalized Medicine Coalition

Dr. Jakob Lange

Account Director

Ypsomed AG

Dr. Beatrix Metzner

Director Global CMC Strategy

Boehringer Ingelheim Pharma

Dr. Ceil Nick

Vice President (Technical)


Dr. Mike Muenzberg

Vice President, Director Medical Affairs Biosimilars


Dr. Steinar Madsen

Medical Director

Norwegian Medicines Agency

Dr. Rodeina Challand

Executive Director, Biosimilars Development – Scientific Affairs




Sponsors and Partners



Media partner

Media partner